Sökning: onr:"swepub:oai:lup.lub.lu.se:a953b917-101c-4a48-8c8d-d7e8898025c4" >
Patient trajectorie...
-
Ekberg, SaraKarolinska Institutet,Karolinska Institute
(författare)
Patient trajectories after diagnosis of diffuse large B-cell lymphoma—a multistate modelling approach to estimate the chance of lasting remission
- Artikel/kapitelEngelska2022
Förlag, utgivningsår, omfång ...
-
2022-08-23
-
Springer Science and Business Media LLC,2022
Nummerbeteckningar
-
LIBRIS-ID:oai:lup.lub.lu.se:a953b917-101c-4a48-8c8d-d7e8898025c4
-
https://lup.lub.lu.se/record/a953b917-101c-4a48-8c8d-d7e8898025c4URI
-
https://doi.org/10.1038/s41416-022-01931-2DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:150529228URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:art swepub-publicationtype
-
Ämneskategori:ref swepub-contenttype
Anmärkningar
-
Background: Achieving lasting remission for at least 2 years is a good indicator for favourable prognosis long term after Diffuse large B-cell lymphoma (DLBCL). The aim of this study was to provide real-world probabilities, useful in risk communication and clinical decision-making, of the chance for lasting remissions by clinical characteristics. Methods: DLBCL patients in remission after primary treatment recorded in the Swedish Lymphoma register 2007–2014 (n = 2941) were followed for relapse and death using multistate models to study patient trajectories. Flexible parametric models were used to estimate transition rates. Results: At 2 years, 80.7% (95% CI: 79.0–82.2) of the patients were predicted to remain in remission and 13.2% (95% CI: 11.9–14.6) to have relapsed. The relapse risk peaked at 7 months, and the annual decline of patients in remission stabilised after 2 years. The majority of patients in the second remission transitioned into a new relapse. The probability of a lasting remission was reduced by 20.4% units for patients with IPI 4–5 compared to patients with IPI 0–1, and time in remission was shortened by 3.5 months. Conclusion: The long-term prognosis was overall favourable with 80% achieving durable first remissions. However, prognosis varied by clinical subgroups and relapsing patients seldom achieved durable second remissions.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Crowther, MichaelKarolinska Institute,Red Door Analytics
(författare)
-
Harrysson, SaraKarolinska Institutet,Karolinska Institute,Karolinska University Hospital
(författare)
-
Jerkeman, MatsLund University,Lunds universitet,Lymfom - Klinisk forskning,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Lymphoma - Clinical Research,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Skåne University Hospital(Swepub:lu)onk-mje
(författare)
-
E. Smedby, KarinKarolinska Institutet,Karolinska Institute,Karolinska University Hospital
(författare)
-
Eloranta, SandraKarolinska Institute
(författare)
-
Karolinska InstitutetKarolinska Institute
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:British Journal of Cancer: Springer Science and Business Media LLC127:9, s. 1642-16490007-09201532-1827
Internetlänk
Hitta via bibliotek
Till lärosätets databas